

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

Goat Anti-Human IgA-HRP

RRID:AB_2687526

Type: Antibody

Proper Citation

SouthernBiotech Cat# 2050-05, RRID:AB_2687526

Antibody Information

URL: http://antibodyregistry.org/AB_2687526

Proper Citation: SouthernBiotech Cat# 2050-05, RRID:AB_2687526

Target Antigen: Human IgA

Host Organism: goat

Clonality: unknown

Antibody Name: Goat Anti-Human IgA-HRP

Description: This unknown targets Human IgA

Target Organism: human

Antibody ID: AB_2687526

Vendor: SouthernBiotech

Catalog Number: 2050-05

Record Creation Time: 20231110T034042+0000

Record Last Update: 20260901T040246+0000

Ratings and Alerts

No rating or validation information has been found for Goat Anti-Human IgA-HRP.

No alerts have been found for Goat Anti-Human IgA-HRP.

Data and Source Information

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Naing L, et al. (2026) TNFRSF13B Common Variants Enhance Antibody-Dependent Complement Activation and Susceptibility to Acute Respiratory Distress Syndrome Following Respiratory Viral Infection. medRxiv : the preprint server for health sciences.

Chan C, et al. (2024) Enhancing Neutrophil Cytotoxicity of a Panel of Clinical EGFR Antibodies by Fc Engineering to IgA3.0. Molecular cancer therapeutics, 23(9), 1317.

Lu S, et al. (2023) Systems serology in cystic fibrosis: Anti-Pseudomonas IgG1 responses and reduced lung function. Cell reports. Medicine, 4(10), 101210.

Deal CE, et al. (2023) An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions. Cell reports. Medicine, 4(11), 101253.

Gonzalez-Miro M, et al. (2023) Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial. iScience, 26(3), 106261.

Lederer K, et al. (2022) Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell, 185(6), 1008.

Lin CY, et al. (2022) Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. Cell host & microbe, 30(1), 83.

Rodda LB, et al. (2022) Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell, 185(9), 1588.

Walls AC, et al. (2022) SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell, 185(5), 872.

Yegorov S, et al. (2022) Inactivated and live-attenuated seasonal influenza vaccines boost broadly neutralizing antibodies in children. Cell reports. Medicine, 3(2), 100509.

Rodda LB, et al. (2021) Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell, 184(1), 169.

Jennewein MF, et al. (2021) Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell reports, 36(2), 109353.

Kim DM, et al. (2021) Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19. Cell reports, 37(1), 109798.

Magri G, et al. (2017) Human Secretory IgM Emerges from Plasma Cells Clonally Related to Gut Memory B Cells and Targets Highly Diverse Commensals. Immunity, 47(1), 118.